Understanding Immunity to the COVID-19 Vaccines

• Sponsor: Stanford University (Other)
• Overall Status: Completed
• CT.gov ID: NCT04664309
• Collaborator: National Institutes of Health (NIH) (NIH)
• Enrollment: 43
• Location: 1
• Actual Duration (Months): 9.4
• Patients Per Site Per Month: 4.6

Study Details

Study Description

Brief Summary

The purpose of this study is to test over time immunity to the COVID-19 vaccines. Adults who are receiving COVID-19 vaccines will be invited to participate.

Condition or Disease	Intervention/Treatment	Phase
COVID-19; Immunity; Vaccine	Other: No intervention

Study Design

• Study Type: Observational
• Actual Enrollment: 43 participants
• Observational Model: Case-Only
• Time Perspective: Prospective
• Official Title: Understanding Immunity to the COVID-19 Vaccines
• Actual Study Start Date: Mar 26, 2021
• Actual Primary Completion Date: Jan 6, 2022
• Actual Study Completion Date: Jan 6, 2022

Arms and Interventions

Arm	Intervention/Treatment
Participants Adults who are receiving a COVID-19 vaccine	Other: No intervention; No intervention

Outcome Measures

Primary Outcome Measures

1. Percentage of participants with immunity to COVID-19 vaccines over time [1 year]

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Inclusion Criteria:

• Adults who are receiving a COVID-19 vaccine

Exclusion Criteria:

• Patients with special risks attendant to venipuncture

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Stanford University, Hospital, and Clinics	Stanford	California	United States	94305

Sponsors and Collaborators

• Stanford University
• National Institutes of Health (NIH)

Investigators

• Principal Investigator: Kari Nadeau, MD, PhD, Stanford University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Kari Christine Nadeau, MD, PhD, Professor of Medicine, Stanford University
• ClinicalTrials.gov Identifier: NCT04664309
• Other Study ID Numbers: IRB-60171
• First Posted: Dec 11, 2020
• Last Update Posted: Feb 28, 2022
• Last Verified: Feb 1, 2022

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Additional relevant MeSH terms: COVID-19

Study Results

No Results Posted as of Feb 28, 2022